Ozempic and Wegovy may cut dementia risk by 45% and manage diabetes, study finds |

A groundbreaking study has revealed that GLP-1 receptor agonists—including popular weight-loss and diabetes drugs like Ozempic, Wegovy, and Mounjaro- may significantly reduce the risk of developing dementia. The analysis, conducted by Irish researchers and published in JAMA Neurology, involved data from over 164,000 participants and found that these medications reduced the risk of memory-robbing disorders by up to 45 per cent. These findings not only open new avenues for neurological protection but also position GLP-1 drugs as powerful tools in both metabolic and cognitive health management.

Study links GLP-1 drugs like Ozempic and Mounjaro to lower dementia risk

Researchers from the University of Galway reviewed 26 clinical trials involving 164,531 individuals—65% of whom were men, with an average age of 64. The participants were followed for an average of 31 months. The key discovery: patients taking GLP-1 agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) were 45% less likely to develop dementia compared to those on other glucose-lowering medications.Dr. Catriona Reddin, senior study author, said, “Our findings suggest that GLP-1 receptor agonists, in particular, may have a protective effect on brain health.”

How GLP-1 agonists may protect against dementia

Although the exact mechanism remains under investigation, researchers propose several pathways through which GLP-1 medications could shield the brain:Reduced neuroinflammation: These drugs may lower inflammation in the brain, which is known to damage neurons and trigger dementia symptoms.Decrease in amyloid and tau proteins: GLP-1 agonists could suppress the accumulation of toxic proteins linked to Alzheimer’s disease.Improved blood vessel health: They may reduce blood pressure and enhance blood flow, preventing vascular dementia.Neurogenesis stimulation: Early research suggests these drugs may promote neural growth in the hippocampus, the brain region essential for memory.

GLP-1 drugs may help prevent both diabetes and dementia

The new study aligns with earlier research from the University of Florida, which followed 400,000 Americans and reported a 33% lower risk of dementia among GLP-1 users compared to other treatments. This growing body of evidence supports the role of semaglutide and tirzepatide not only in treating type 2 diabetes and obesity but potentially in preventing cognitive decline.Professor Martin O’Donnell, Dean at the University of Galway, emphasised, “With both diabetes and dementia rising, these findings have major public health implications.”

Dementia and diabetes: Twin epidemics in the US

The study arrives amid alarming trends:

According to the Alzheimer’s Association, Alzheimer’s rates have climbed 25 consecutive years.The intersection of these two epidemics highlights the urgency of therapies that can address both conditions simultaneously.

Study highlights need for more GLP-1 brain health data

While the findings are promising, researchers caution that more work is needed to confirm the results. Notable limitations include:

Originally celebrated as breakthrough treatments for obesity and diabetes, these medications may now be poised to take on an even broader role in preventing neurodegenerative diseases.As Dr. Reddin concluded, “This research marks a significant advancement in how we understand the brain benefits of diabetes medications.”*Disclaimer: This article is based on findings from a study published in JAMA Neurology (July 2024). While the research links GLP-1 drugs like Ozempic and Mounjaro to reduce dementia risk, it is observational and does not prove direct causation. Further studies are needed. Always consult a healthcare provider before making medication decisions.Also Read | 5 coffee routine habits that could be doing more harm than good, say experts